Funding for this research was provided by:
Agency for Science, Technology and Research (JCO 1334k00083)
Received: 29 October 2020
Accepted: 15 January 2021
First Online: 5 February 2021
Ethics approval and consent to participate
: The use of human patient-derived cells was conducted with informed consent obtained for each subject, approved by the National Healthcare Group Domain Specific Review Board, Singapore (2009/00376 and 2014/00396), and performed in accordance with its relevant regulations.
: Not applicable
: The BDL-E5 probe and its applications were filed for patent by Sa. Sr, Sh. Su, Y.T.C., and N.Y.K. (PCT/SG2018/050329). Sh. Su is a co-founder of the Celligenics Pte. Ltd., which has not had any influence to this study. Other authors declare that they have no other competing interests.